BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding BioCardia, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 9 | 13 | +4 |
| Shares | 101.5K | 124.8K | +23.4K (+23.0%) |
| Value | $316.6K | $272.2K | −$44.5K (−14.0%) |
New holders (4)
Institutions that held BioCardia, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| CM Management, LLC | 25,000 | $54.5K | 0.05% |
| UBS Group AG | 4,750 | $10.4K | 0.00% |
| JPMorgan Chase & Co | 899 | $1.96K | 0.00% |
| SBI Securities Co., Ltd. | 15 | $33 | 0.00% |
Sold out (0)
Institutions that held BioCardia, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
None.